DRUGSwww.epgonline.orgDISEASE KNOWLEDGE CENTRESwww.epgonline.orgGUIDELINESwww.epgonline.orgCLINICAL TRIALSwww.epgonline.orgMEDICAL NEWSwww.epgonline.orgLINKSwww.epgonline.org
Members Login
How to use the
Email

Password



EPG News Feed Medical News Feed
EPG Online Disease Knowledge Centres Feed Knowledge Centres Feed
EPG Search
Frequent Searches:
Search
Languages

Browse Other Languages
YouTube - Featured Content

Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here

epgonline.org is not responsible for content on any 3rd party website

Men's Health - understanding, management, diagnosis and treatment information Benign prostatic hyperplasia (BPH) - understanding, management, diagnosis and treatment information Parkinson's Disease - understanding, management, diagnosis and treatment information. Medical conferences for the Healthcare professional
Are you a Doctor or Healthcare Professional? Authorise Viewing

Please register to access disease diagnosis, patient management, physician tools.

By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.

Change language Current language database: United Kingdom

A  |  B  |  C  |  D  |  E  |  F  |  G  |  H  |  I  |  J  |  K  |  L  |  M
N  |  O  |  P  |  Q  |  R  |  S  |  T  |  U  |  V  |  W  |  X  |  Y  |  Z

Drug details for : MANERIX
 
Drug class description :  Reversible MAO-A inhibitors (reversible MAOIs, antidepressants).
Generic Name :  Moclobemide
Drug description :  Yellow scored oblong f-c tablets, 300 mg white scored oblong f-c tablets. Both marked ROCHE and tablet strength.
Presentation :  Tablets, moclobemide 150 mg , 300mg .
Indications :  Major depression. Social phobia.
Adult Dosage :  Depression, initially 300 mg daily in divided doses, after meals; maximum 600 mg daily. Social phobia, 300 mg daily for three days, then 600 mg daily in 2 divided doses for 8 - 12 weeks. Then assess.
Child Dosage :  Not recommended.
Contra Indications :  Acute confusional states, phaeochromocytoma.
Special Precautions :  Severe hepatic impairment, thyrotoxicosis. Patients with excitation or agitiation as predominant feature or schizophrenia. Pregnancy, lactation. Avoid excessive amounts of tyramine rich food.
Interactions :  Pethidine, selegiline, 5-HT reuptake inhibitors, tricyclic and tetracyclic antidepressants, trazodone, tyramine, cimetidine, morphine, fentanyl, ephedrine, pseudoephedrine, phenylpropanolamine, dextromethorphan.
Adverse Reactions :  Sleep disturbances, agitation, restlessness, irritability, dizziness, headache, paraesthesia, dry mouth, visual disturbances, nausea, diarrhoea, constipation, vomiting, oedema, states.
Manufacturer :  Roche
Drug Availability :  (POM)
Free registration to access disease diagnosis, patient management, physician tools.

Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.

Already Registered?

Please log-in now using our member login box.

Not a member?

Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.

Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.

As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!

REGISTER today it only takes a minute! and it's FREE

Having problems?

Use our forgotten password facility or email us at: contact@epgonline.org

What's New!
Try EPG Mobile
Latest News
Disease Knowledge Centres

EPG Survey Become a member of
the new EPG Survey Panel.
Your opinions matter, get paid for them! Join Now!